Preoperative and postoperative prognostic factors of patients with stage II/III lower rectal cancer without neoadjuvant therapy in the clinical trial (JCOG0212).
Masayuki OhueShin FujitaJunki MizusawaYukihide KanemitsuTetsuya HamaguchiShunsuke TsukamotoShingo NouraMasayoshi YasuiMasaaki ItohAkio ShiomiKoji KomoriJun WatanabeYoshihiro AkazaiManabu ShiozawaTakashi YamaguchiHiroyuki BandouKenji KatsumataYoshihiro MoriyaPublished in: Japanese journal of clinical oncology (2021)
Clinical stage II/III lower rectal cancer patients with cT4a should be a target of therapeutic development of neoadjuvant therapy. Postoperatively, intensive chemotherapy should be investigated for patients with more metastatic lymph nodes.
Keyphrases
- rectal cancer
- locally advanced
- prognostic factors
- lymph node
- neoadjuvant chemotherapy
- clinical trial
- squamous cell carcinoma
- patients undergoing
- small cell lung cancer
- radiation therapy
- computed tomography
- magnetic resonance
- stem cells
- magnetic resonance imaging
- high resolution
- randomized controlled trial
- cell therapy
- phase iii
- bone marrow
- open label
- sentinel lymph node
- study protocol
- early stage
- image quality
- mesenchymal stem cells
- phase ii